Promising antibody trial aims to halt rare bone disease in kids
NCT ID NCT07559513
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests garetosmab, an antibody that blocks activin A, in 18 children and teens with fibrodysplasia ossificans progressiva (FOP), a rare disease where muscle and tissue turn into bone. The study will check safety, side effects, and whether the drug reduces new abnormal bone growth and flare-ups. Participants receive the drug by infusion, and the trial is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
garetosmab (a lab-made antibody that blocks activin A)
What this could lead to
If it works, this could slow or prevent the formation of extra bone in children with FOP, reducing painful flare-ups and preserving mobility.
What could go wrong
This is an early Phase 3 trial with only 18 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••